| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/INFDIS/JIU043 |
| P698 | PubMed publication ID | 25316866 |
| P50 | author | Mark A. Pallansch | Q84361194 |
| Roland W Sutter | Q90470465 | ||
| M Steven Oberste | Q92072873 | ||
| Marc S Collett | Q116996575 | ||
| P2093 | author name string | Jeffrey R Hincks | |
| Mark A McKinlay | |||
| Walter R Dowdle | |||
| John F Modlin | |||
| Hiromasa Okayasu | |||
| P2860 | cites work | VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION * | Q22255613 |
| Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design | Q27730329 | ||
| Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials | Q28178690 | ||
| Software extensions to UCSF chimera for interactive visualization of large molecular assemblies | Q28239660 | ||
| Oral efficacy of WIN 51711 in mice infected with human poliovirus | Q28362056 | ||
| No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala | Q29544377 | ||
| Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses | Q30447033 | ||
| In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease | Q30448335 | ||
| Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. | Q30448643 | ||
| Treatment of potentially life-threatening enterovirus infections with pleconaril | Q31918011 | ||
| Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis | Q33827773 | ||
| Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole | Q36265401 | ||
| Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. | Q36364228 | ||
| Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management | Q36690341 | ||
| Changes in population dynamics during long term evolution of Sabin type 1 poliovirus in an immunodeficient patient | Q36898727 | ||
| A case for developing antiviral drugs against polio | Q37177805 | ||
| In vitro antiviral activity of V-073 against polioviruses | Q37392839 | ||
| Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. | Q37423069 | ||
| Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds | Q39180349 | ||
| Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. | Q39453436 | ||
| Inhibition of uncoating of poliovirus by arildone, a new antiviral drug | Q40248804 | ||
| Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice | Q42849256 | ||
| Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. | Q44890455 | ||
| Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient | Q45222453 | ||
| Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. | Q50183859 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eradication of infectious diseases | Q1347969 |
| Poliovirus | Q70923324 | ||
| P304 | page(s) | S447-53 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication | |
| P478 | volume | 210 Suppl 1 |
| Q90424115 | 2'-C-methylated nucleotides terminate virus RNA synthesis by preventing active site closure of the viral RNA-dependent RNA polymerase |
| Q33568783 | Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model |
| Q35968325 | Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame |
| Q37542082 | Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. |
| Q36571245 | Enteroviruses in the early 21st century: new manifestations and challenges |
| Q91974621 | Facility-Associated Release of Polioviruses into Communities-Risks for the Posteradication Era |
| Q47179826 | Global Polio Eradication - Way Ahead |
| Q92238908 | Host Genetics, Innate Immune Responses, and Cellular Death Pathways in Poliomyelitis Patients |
| Q33564108 | Investigation of the Role of Protein Kinase D in Human Rhinovirus Replication |
| Q41924068 | MicroRNA-134 regulates poliovirus replication by IRES targeting. |
| Q35779733 | Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. |
| Q28076138 | My Cousin, My Enemy: quasispecies suppression of drug resistance |
| Q41779600 | Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication |
| Q40838379 | Polio endgame: the global switch from tOPV to bOPV. |
| Q41921219 | Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry |
| Q54226906 | Structure-Function Mutational Analysis and Prediction of the Potential Impact of High Risk Non-Synonymous Single-Nucleotide Polymorphism on Poliovirus 2A Protease Stability Using Comprehensive Informatics Approaches. |
| Q35757398 | Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative. |
| Q90918713 | Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters |
Search more.